Segundo Rite Gracia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Segundo Rite Gracia has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Alejandro Pérez Muñuzuri
Hospital Clínico Universitario, Santiago de Compostela, España
3 shared publicationsCésar W. Ruiz Campillo
Hospital Universitario Vall d'Hebron, Barcelona, España
3 shared publicationsEster Sanz López
Hospital General Universitario Gregorio Marañón, Madrid, España
3 shared publicationsJosé Luis Leante Castellanos
Hospital General Universitario Santa Lucía, Cartagena, España
3 shared publications- Manuel Sánchez-Luna
Neonatology Department, Gregorio Marañón University General Hospital, Complutense University of Madrid, FISGM, Madrid, Spain
3 shared publications Gemma Ginovart Galiana
Servicio de Neonatología, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
2 shared publications
Latest Publications
- 12 August 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1
Clarification on the legal and training status of Neonatology in Spain
- 12 August 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1
Clarification on the legal and training status of Neonatology in Spain
- Open Access
- 1 November 2024
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 101 (5) , 319-330
Management of respiratory distress syndrome in moderate/late preterm neonates: A Delphi consensus
- 1 November 2024
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 101 (5) , 319-330
Open AccessManagement of respiratory distress syndrome in moderate/late preterm neonates: A Delphi consensus
- Open Access
- 22 October 2024
- Published by Elsevier in Anales de Pediatría
- Vol. 101 (5) , 319-330
Manejo del síndrome de distrés respiratorio en recién nacidos prematuros moderados/tardíos: consenso Delphi
- 22 October 2024
- Published by Elsevier in Anales de Pediatría
- Vol. 101 (5) , 319-330
Open AccessManejo del síndrome de distrés respiratorio en recién nacidos prematuros moderados/tardíos: consenso Delphi
- Open Access
- 4 February 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 830035
The Consensus Definition of Bronchopulmonary Dysplasia Is an Adequate Predictor of Lung Function at Preschool Age
Background: Recent attempts to refine the definition bronchopulmonary dysplasia (BPD) have based its predictive capacity on respiratory outcome in the first 2 years of life, eliminating the pre-existing requirement of 28 days of oxygen therapy prior to 36 weeks postmenstrual age (PMA). The objective of this study was to assess the utility of the 2001 consensus definition in predicting impaired lung function at preschool age.Methods: This cohort study included children aged 4–6 years old who were born at gestational age (GA) 0.75]: −1.18 ± 0.80 vs. −0.55 ± 1.13; p = 0.010), but no difference in forced vital capacity (FVC) was observed (−0.32 ± 0.90 vs. −0.18 ± 1; p = 0.534). The moderate-to-severe BPD group exhibited the most severe FEV0.75 reduction (FEV0.75: −2.63 ± 1.18 vs. −0.72 ± 1.08; p = 0.000) and was the only condition with FVC impairment (FVC: −1.82 ± 1.12 vs. −0.22 ± 0.87; p = 0.000). The multivariate analysis identified a diagnosis of moderate-to-severe BPD as an independent risk factor for lung function impairment.Conclusion: The 2001 consensus definition of BPD has adequate predictive capacity for lung function measured by spirometry at 4–6 years of age. Moderate-to-severe BPD was the best predictor of respiratory impairment. Children with mild BPD showed greater alteration of FEV0.75 than those without BPD.
- 4 February 2022
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 830035
Open AccessThe Consensus Definition of Bronchopulmonary Dysplasia Is an Adequate Predictor of Lung Function at Preschool Age
Background: Recent attempts to refine the definition bronchopulmonary dysplasia (BPD) have based its predictive capacity on respiratory outcome in the first 2 years of life, eliminating the pre-existing requirement of 28 days of oxygen therapy prior to 36 weeks postmenstrual age (PMA). The objective of this study was to assess the utility of the 2001 consensus definition in predicting impaired lung function at preschool age.Methods: This cohort study included children aged 4–6 years old who were born at gestational age (GA) 0.75]: −1.18 ± 0.80 vs. −0.55 ± 1.13; p = 0.010), but no difference in forced vital capacity (FVC) was observed (−0.32 ± 0.90 vs. −0.18 ± 1; p = 0.534). The moderate-to-severe BPD group exhibited the most severe FEV0.75 reduction (FEV0.75: −2.63 ± 1.18 vs. −0.72 ± 1.08; p = 0.000) and was the only condition with FVC impairment (FVC: −1.82 ± 1.12 vs. −0.22 ± 0.87; p = 0.000). The multivariate analysis identified a diagnosis of moderate-to-severe BPD as an independent risk factor for lung function impairment.Conclusion: The 2001 consensus definition of BPD has adequate predictive capacity for lung function measured by spirometry at 4–6 years of age. Moderate-to-severe BPD was the best predictor of respiratory impairment. Children with mild BPD showed greater alteration of FEV0.75 than those without BPD.
- 31 January 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 102, 67-70
CYB5R3 homozygous pathogenic variant as a rare cause of cyanosis in the newborn
- 31 January 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 102, 67-70
CYB5R3 homozygous pathogenic variant as a rare cause of cyanosis in the newborn
- Open Access
- 1 March 2021
- Published by Elsevier in Anales de Pediatría
- Vol. 94 (3) , 127-128
Medicamentos off-label y sin licencia en neonatología
- 1 March 2021
- Published by Elsevier in Anales de Pediatría
- Vol. 94 (3) , 127-128
Open AccessMedicamentos off-label y sin licencia en neonatología
- Open Access
- 23 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2362
Rapid Phenotype-Driven Gene Sequencing with the NeoSeq Panel: A Diagnostic Tool for Critically Ill Newborns with Suspected Genetic Disease
New genomic sequencing techniques have shown considerable promise in the field of neonatology, increasing the diagnostic rate and reducing time to diagnosis. However, several obstacles have hindered the incorporation of this technology into routine clinical practice. We prospectively evaluated the diagnostic rate and diagnostic turnaround time achieved in newborns with suspected genetic diseases using a rapid phenotype-driven gene panel (NeoSeq) containing 1870 genes implicated in congenital malformations and neurological and metabolic disorders of early onset (<2 months of age). Of the 33 newborns recruited, a genomic diagnosis was established for 13 (39.4%) patients (median diagnostic turnaround time, 7.5 days), resulting in clinical management changes in 10 (76.9%) patients. An analysis of 12 previous prospective massive sequencing studies (whole genome (WGS), whole exome (WES), and clinical exome (CES) sequencing) in newborns admitted to neonatal intensive care units (NICUs) with suspected genetic disorders revealed a comparable median diagnostic rate (37.2%), but a higher median diagnostic turnaround time (22.3 days) than that obtained with NeoSeq. Our phenotype-driven gene panel, which is specific for genetic diseases in critically ill newborns is an affordable alternative to WGS and WES that offers comparable diagnostic efficacy, supporting its implementation as a first-tier genetic test in NICUs.
- 23 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2362
Open AccessRapid Phenotype-Driven Gene Sequencing with the NeoSeq Panel: A Diagnostic Tool for Critically Ill Newborns with Suspected Genetic Disease
New genomic sequencing techniques have shown considerable promise in the field of neonatology, increasing the diagnostic rate and reducing time to diagnosis. However, several obstacles have hindered the incorporation of this technology into routine clinical practice. We prospectively evaluated the diagnostic rate and diagnostic turnaround time achieved in newborns with suspected genetic diseases using a rapid phenotype-driven gene panel (NeoSeq) containing 1870 genes implicated in congenital malformations and neurological and metabolic disorders of early onset (<2 months of age). Of the 33 newborns recruited, a genomic diagnosis was established for 13 (39.4%) patients (median diagnostic turnaround time, 7.5 days), resulting in clinical management changes in 10 (76.9%) patients. An analysis of 12 previous prospective massive sequencing studies (whole genome (WGS), whole exome (WES), and clinical exome (CES) sequencing) in newborns admitted to neonatal intensive care units (NICUs) with suspected genetic disorders revealed a comparable median diagnostic rate (37.2%), but a higher median diagnostic turnaround time (22.3 days) than that obtained with NeoSeq. Our phenotype-driven gene panel, which is specific for genetic diseases in critically ill newborns is an affordable alternative to WGS and WES that offers comparable diagnostic efficacy, supporting its implementation as a first-tier genetic test in NICUs.
- Open Access
- 1 November 2019
- Published by Elsevier in Anales de Pediatría
- Vol. 91 (5) , 348-350
Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización
- 1 November 2019
- Published by Elsevier in Anales de Pediatría
- Vol. 91 (5) , 348-350
Open AccessRecomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización
- Open Access
- 19 October 2019
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 91 (5) , 348-350
An update of the recommendations of the spanish neonatology society for the use of paivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants
- 19 October 2019
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 91 (5) , 348-350
Open AccessAn update of the recommendations of the spanish neonatology society for the use of paivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants
- 3 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (7) , e2838
Metabolic changes and crystallographic profile in hyperparathyroidism patients with stone disease
- 3 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (7) , e2838
Metabolic changes and crystallographic profile in hyperparathyroidism patients with stone disease